Hyper Phosphatemia In Chronic Kidney Disease - Pipeline Review, Q2 2011

Hyper Phosphatemia In Chronic Kidney Disease - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Hyper Phosphatemia In Chronic Kidney Disease - Pipeline Review, Q2 2011', provides an overview of the Hyper Phosphatemia In Chronic Kidney Disease therapeutic pipeline. This report provides information on the therapeutic development for Hyper Phosphatemia In Chronic Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyper Phosphatemia In Chronic Kidney Disease. 'Hyper Phosphatemia In Chronic Kidney Disease - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Hyper Phosphatemia In Chronic Kidney Disease.
• A review of the Hyper Phosphatemia In Chronic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Hyper Phosphatemia In Chronic Kidney Disease pipeline on the basis of therapeutic class, route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Hyper Phosphatemia In Chronic Kidney Disease.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Hyper Phosphatemia In Chronic Kidney Disease pipeline depth and focus of Hyper Phosphatemia In Chronic Kidney Disease therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hyper Phosphatemia In Chronic Kidney Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Hyper Phosphatemia In Chronic Kidney Disease
Hyper Phosphatemia In Chronic Kidney Disease Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Hyper Phosphatemia In Chronic Kidney Disease Therapeutics - Products under Development by Companies
Companies Involved in Hyper Phosphatemia In Chronic Kidney Disease Therapeutics Development
Amgen Inc.
Acologix, Inc.
Panion & Bf Biotech Inc.
Cytochroma Inc.
Hyper Phosphatemia In Chronic Kidney Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG 223 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AMG 223 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Nephoxil - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AC-200 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
CTAP101 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Hyper Phosphatemia In Chronic Kidney Disease Therapeutics – Drug Profile Updates
Hyper Phosphatemia In Chronic Kidney Disease Therapeutics - Discontinued Products
Hyper Phosphatemia In Chronic Kidney Disease - Featured News
Mar 07, 2011: Keryx Biopharmaceuticals Announces Oral Presentation Of Final Zerenex Short-Term Phase III Data At Upcoming National Kidney Foundation's 2011 Spring Clinical Meetings
Jan 05, 2010: Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement With FDA For Phase III Registration Program Of Zerenex
Oct 11, 2009: XOMA and Millennium entered into an agreement in November 2001
Jun 08, 2009: Keryx Biopharmaceuticals Reports Positive Phase II Study Results Of Zerenex For The Treatment Of Hyperphosphatemia In End-Stage Renal Disease Patients
Feb 06, 2007: Ilypsa, Inc. Announces Completion Of Enrollment Of Phase 2 Clinical Trial of ILY101
Jun 29, 2006: Keryx Announces Positive Final Results From Phase II Dose-Ranging Study Of Zerenex For The Treatment Of Hyperphosphatemia In Patients With End-stage Renal Disease
Apr 27, 2006: Ilypsa And Astellas Enter A Licensing Agreement On ILY101 For Treatment Of Hyperphosphatemia In Japan
Apr 20, 2006: Ilypsa Completes Phase 1 Clinical Trial Of ASP1585 (ILY101)
Feb 15, 2006: Keryx Biopharmaceuticals Announces Expansion Of Renal Franchise With The In-Licensing Of Zerenex
Oct 16, 2000: Clinical Trial Results for Hectorol in Pre-Dialysis Renal Patients was announced by Bone Care International.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 37

LIST OF TABLES

Number of Products Under Development for Hyper Phosphatemia In Chronic Kidney Disease, Q2 2011
Products under Development for Hyper Phosphatemia In Chronic Kidney Disease – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Amgen Inc., 2011
Acologix, Inc., 2011
Panion & Bf Biotech Inc., 2011
Cytochroma Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Hyper Phosphatemia In Chronic Kidney Disease Therapeutics – Drug Profile Updates
Discontinued Products 30

LIST OF FIGURES

Number of Products under Development for Hyper Phosphatemia In Chronic Kidney Disease, Q2 2011
Products under Development for Hyper Phosphatemia In Chronic Kidney Disease – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011 20 Skip to top